Feature | ASTRO | October 30, 2018

Late-breaking Radiation Therapy Clinical Trials at ASTRO 2018

ASTRO 2018 Radiation Therapy Clinical Trials. #ASTRO2018 #ASTRO18 #ASTRO

October 30, 2018 — The American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting included 10 top-rated clinical studies. The ASTRO 2018 annual meeting, held Oct. 21-23 in San Antonio, Texas drews more than 11,000 attendees.

The highlighted studies below are linked to full articles. 

 

Advances in Breast and Lung Cancers

Sunday, Oct. 21

 

Advances in Genitourinary Cancers

Monday, Oct. 22

 

Advances in Oral and Oligometastatic Cancers

Tuesday, Oct. 23

 

Other ASTRO News and Videos:

Trends in Proton Therapy at ASTRO 2018 — Faster Therapy Delivery, Single-room Installs

 

SBRT Considered Safe Treatment Option for Patients With Multiple Metastases

VIDEO: Radiation Oncology Reimbursement Update From ASTRO — Interview with Anne Hubbard, MBA, ASTRO director of health policy

Hippocampal Sparing Prevents Whole-Brain Radiotherapy Cognitive Side Effects

VIDEO: Biologically Guided Radiation Therapy Using Real-time PET Imaging — Interview with Kristin Higgens, M.D., Emory 

Smart Machines To Empower Oncology Docs and Patients, Say ASTRO Experts

VIDEO: Beaumont's Experience With Proton Therapy After One Year — Interview with Peyman Kabolizadeh, M.D., Beaumont Proton Therapy Center

Biology Guided Radiotherapy May Improve Physician Confidence in Treatment of Multiple Tumors

VIDEO: The Use of Nanoparticles in Radiation Therapy — Interview with James Welsh, M.D., MD Anderson Cancer Center

Market for MRI-based RT Could Soon Widen

VIDEO: FDA-cleared Bra Helps Improve Breast Positioning During Radiation Therapy — Interview with Elizabeth Chabner-Thompson, M.D., MPH

Prostate Brachytherapy Shows Low Incidence of Short-Term Complications

VIDEO: Use of Liquid Biopsies to Assess Radiotherapy Response — Interview with Aadel Chaudhuri, M.D.

360 View of the Dedicated Radiotherapy Magnetom Sola 1.5T MRI System

VIDEO: Personalizing Radiotherapy Using Genomic Markers of Radiosensitivity — Interview with Javier Torres-Roca, M.D.

VIDEO: Improving Breast Cancer Surgery With Electronic Brachytherapy IORT —  Interview with A. M. Niser Syed, M.D.

360 View of a GE Healthcare Discovery RF Gen 2 Dedicated Radiation Therapy CT System
 

 

 

For more information: www.astro.org

Related Content

Greater Left Ventricular Mass Increases Risk of Heart Failure
News | Cardiac Imaging | October 21, 2019
Elevated left ventricular mass, known as left-ventricular hypertrophy, is a stronger predictor of coronary artery...
MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost
Videos | Radiation Oncology | October 11, 2019
Lorraine Drapek, DNP, nurse practitioner, radiation oncology, GI service,...
Sponsored Content | Whitepapers | Clinical Trials | October 09, 2019
A 2019 N G PX REPORT
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
ProTom International received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radiance 330 proton therapy system
News | Proton Therapy | October 07, 2019
ProTom International received 510(k) clearance from the U.S.